Inflarx (NASDAQ: CDMO) and Avid Bioservices (NASDAQ:CDMO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.
This table compares Inflarx and Avid Bioservices’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings for Inflarx and Avid Bioservices, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Inflarx presently has a consensus target price of $42.67, suggesting a potential upside of 29.18%. Avid Bioservices has a consensus target price of $8.75, suggesting a potential upside of 22.21%. Given Inflarx’s higher possible upside, equities analysts plainly believe Inflarx is more favorable than Avid Bioservices.
Valuation and Earnings
This table compares Inflarx and Avid Bioservices’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Avid Bioservices||$53.62 million||7.48||-$21.81 million||($0.50)||-14.32|
Avid Bioservices has higher revenue and earnings than Inflarx. Avid Bioservices is trading at a lower price-to-earnings ratio than Inflarx, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
54.8% of Inflarx shares are owned by institutional investors. Comparatively, 21.7% of Avid Bioservices shares are owned by institutional investors. 0.9% of Avid Bioservices shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Inflarx beats Avid Bioservices on 7 of the 11 factors compared between the two stocks.
Inflarx Company Profile
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases. It also develops IFX-2 for the treatment of chronic inflammation and autoimmune diseases. The company has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Avid Bioservices Company Profile
Avid Bioservices, Inc., a biologics contract development and manufacturing company, focuses on the development and current Good Manufacturing Practices (cGMP) manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, cGMP clinical, and commercial manufacturing services for the biotechnology and biopharmaceutical industries. The company produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and offers services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission, and support. It also provides various process development services, such as cell line development and optimization, cell culture and feed optimization, analytical methods development, and product characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.
Receive News & Ratings for Inflarx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Inflarx and related companies with MarketBeat.com’s FREE daily email newsletter.